The trial will enroll up to 57 subjects. Qualified normal healthy volunteers will be enrolled in the study to receive the vaccine or placebo vaccine. Subjects will receive 2 vaccinations with a needle and will be followed for 6 months to evaluate the safety of and the immune system's response to the vaccine. The safety and immune system response will be studied throughout the trial.

Inclusion Criteria:

• 18 to 45 years of age
• Able to provide informed consent and be followed for 6 months

Exclusion Criteria:

• No immunomodulatory therapy within the past 6 months
• No evidence of immunodeficiency or pregnancy
• No laboratory or evidence of clinically significant medical disease
• No history of previous pDNA immunization
• No influenza immunization within the past 30 days
• No blood donations within 30 days of screening visit
• No history of bleeding disorder
• No use of aspirin and/or anticoagulants within 2 weeks of the administration of the investigational vaccines